Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKB238 vs Avastin in advanced non-squamous NSCLC
NCT02810457Phase 3Completed
- Sponsor
- Centus Biotherapeutics
- Start
- Sep 2016
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab-equi in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Centus Biotherapeutics. Primary endpoint: Overall Response Rate up to 30 months. Started Sep 2016; status: completed.
02
Drugs
bevacizumab-equi
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02810457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810457.